Gastrointestinal luminal drugs and solutes

Gastrointestinal luminal drugs and solutes encompass the diverse array of molecules, ions, and substances found within the cavity of the digestive tract, including dietary nutrients, electrolytes, bile acids, and ingested toxins. While not a single protein or receptor, this environment serves as a critical site for therapeutic intervention using non-absorbed agents that bind or modify these solutes (StatPearls, NBK526095). For example, phosphate binders like sevelamer are used to manage hyperphosphatemia in chronic kidney disease by sequestering dietary phosphorus within the gut (PubMed, 30219112). Similarly, potassium binders such as patiromer facilitate the fecal excretion of potassium to treat hyperkalemia (FDA, Veltassa Label). Bile acid sequestrants lower systemic cholesterol by interrupting the enterohepatic circulation of bile salts, forcing the liver to use more cholesterol for bile acid synthesis (StatPearls, NBK526095). Furthermore, activated charcoal acts as a non-specific adsorbent to prevent the systemic absorption of various poisons and drug overdoses (StatPearls, NBK482294). Targeting luminal solutes allows for localized action within the GI tract, often reducing the risk of systemic toxicity associated with absorbed medications.

Other names

GI luminal contentsIntestinal solutesLuminal substancesGastrointestinal contents

Non-systemic sequestration, chelation, or physical adsorption of luminal substances (such as phosphate, potassium, bile acids, or toxins) to prevent their absorption into the bloodstream or to promote their elimination via feces.